Conversely, targeting endogenous EPO using recombinant soluble EPOR (sEPOR) or a neutralizing anti-EPO monoclonal antibody co-injected into window chambers with mammary carcinoma cells inhibits the initiation of tumor angiogenesis and delays growth during the initial stages of tumorigenesis. Here, EPOR is linked to breast carcinoma.